Compound Contains Two Or More C(=o)o Groups Indirectly Bonded Together By Only Conalent Bonds Patents (Class 514/533)
-
Publication number: 20130035389Abstract: This invention relates to methods, assays, devices and systems for identifying patients having a myelodysplastic syndrome for treatment with ezatiostat or a salt thereof, or evaluating the patient's response possibility to the treatment by measuring and evaluating the patient's gene expression profile. This invention also relates to methods of treating myelodysplastic syndromes.Type: ApplicationFiled: April 2, 2012Publication date: February 7, 2013Inventor: Gail L. Brown
-
Publication number: 20130035388Abstract: This patent pertains to selective inhibition of assembly of the membrane attack complex of complement by use of less than 1 kDa molecular weight forms of the aurin tricarboxylic acid synthetic complex (ATAC), and their derivatives. It further pertains to the use of these materials to treat human conditions where there is evidence of self destruction of host tissue by the membrane attack complex. These diseases include, but are not limited to, Alzheimer disease, age related macular degeneration, and atherosclerosis.Type: ApplicationFiled: August 1, 2011Publication date: February 7, 2013Inventors: Patrick L. McGeer, Moonhee Lee, Jian-Ping Guo, Claudia Schwab
-
Publication number: 20130017284Abstract: Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine.Type: ApplicationFiled: July 13, 2012Publication date: January 17, 2013Inventors: Michael Zemel, E. Douglas Grindstaff, II, Antje Bruckbauer
-
Publication number: 20130017283Abstract: Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions can contain synergizing amounts of a sirtuin-pathway activators, including but not limited to resveratrol, in combination with beta-hydroxymethylbutyrate (HMB), keto isocaproic acid (KIC), leucine, or combinations of HMB, KIC and leucine.Type: ApplicationFiled: July 13, 2012Publication date: January 17, 2013Inventors: Michael ZEMEL, E. Douglas Grindstaff, II, Antje Bruckbauer
-
Publication number: 20130004577Abstract: A main object of the present invention is to provide a novel coated tablet which contains a drug having a guanidino group and does not suffer an obvious color change even when packed in a one-dose pack together with a drug having a (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (DMDO) group. The present invention provides a coated tablet characterized in that an uncoated tablet containing a drug having a guanidino group has been coated with a polyvinyl alcohol for film coating which comprises polyvinyl alcohol, acrylic acid, and methyl methacrylate.Type: ApplicationFiled: September 7, 2012Publication date: January 3, 2013Applicant: NIPPON SHINYAKUInventors: Hironobu KATO, Hirokazu SAKAMOTO
-
Publication number: 20130005767Abstract: Disclosed herein are compounds of the formula or salts or bioisosteres thereof. Therapeutic methods, medicaments, and compositions related thereto are also disclosed.Type: ApplicationFiled: September 14, 2012Publication date: January 3, 2013Applicant: Allergan, Inc.Inventors: David W. Old, Vinh X. Ngo
-
Publication number: 20120329871Abstract: A compound for use as an antimicrobial having a formula (A).Type: ApplicationFiled: December 21, 2010Publication date: December 27, 2012Applicant: THE UNIVERSITY OF WESTERN AUSTRALIAInventors: Allan James McKinley, Thomas V. Riley, Nigel Lengkeek, Scott Stewart, Ramiz Boulos
-
Publication number: 20120328541Abstract: Compounds of the formulae and selected hindered nitroxyl, hydroxylamine and hydroxylamine salt compounds such as the compound of the formula wherein G1 is hydrogen; C1-C22alkyl; C1-C22alkylthio; C2-C22alkylthioalkyl; C5-C7cycloalkyl; phenyl; C7-C9-phenylalkyl; or SO3M; G2 is C1-C22alkyl; C5-C7cycloalkyl; phenyl; or C7-C9-phenylalkyl; E is oxyl or hydroxyl; V is —O—; or —NH—; a is 0 or 1 or 2; b, c and d and g are each independently of one another 0 or 1; e is an integer from 1 to 4; f, m, n and p are each independently of one another an integer from 1 to 3; q is 0 or an integer from 1 to 3; Q, T and G3 are as defined in claim 1; G4 and G5 are each independently of the other hydrogen; or C1-C22alkyl; exhibit marked antiinflammatory action.Type: ApplicationFiled: September 5, 2012Publication date: December 27, 2012Inventors: Werner Baschong, Oliver Reich, Sébastien Mongiat
-
Publication number: 20120309693Abstract: The present disclosure serves to reduce the healing time of tissue wounds, including those formed during surgery, whether necessary or elective (including cosmetic surgery), by providing a therapeutic dose of a pancreatic enzyme inhibitor.Type: ApplicationFiled: September 28, 2010Publication date: December 6, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Frank A. DeLano, Geert W. Schmid-Schonbein
-
Patent number: 8324272Abstract: Levodopa dimethyl-substituted diester prodrugs pharmaceutical, compositions comprising levodopa dimethyl-substituted diester prodrugs, and methods of using such prodrugs and pharmaceutical compositions for treating diseases such as Parkinson's disease are provided.Type: GrantFiled: March 18, 2010Date of Patent: December 4, 2012Assignee: XenoPort, Inc.Inventors: Jia-Ning Xiang, Cindy X. Zhou, Fenmei Yao, Mark Q. Nguyen
-
Patent number: 8324273Abstract: Catechol protected levodopa diester prodrugs pharmaceutical, compositions comprising catechol protected levodopa diester prodrugs, and methods of using such prodrugs and pharmaceutical compositions for treating diseases such as Parkinson's disease are provided.Type: GrantFiled: October 14, 2010Date of Patent: December 4, 2012Assignee: XenoPort, Inc.Inventors: Jia-Ning Xiang, Cindy X. Zhou, Fenmei Yao, Mark Q. Nguyen
-
Publication number: 20120302636Abstract: Provided is a method of treating or preventing a disorder in a subject comprising administering twice per day a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrate thereof, to a subject that has or is at risk of having a disorder selected from the group consisting of hyperlipidemia, arteriosclerosis, coronary artery diseases, metabolic syndrome, obesity, diabetes, prediabetes, and hypertension, whereupon the disorder is treated or prevented in the subject. The method optionally comprises administering a therapeutically effective amount of the compound of formula (I), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, to the subject, in which the therapeutically effective amount is increased once or twice during the course of administration.Type: ApplicationFiled: December 16, 2011Publication date: November 29, 2012Inventors: Harutoshi KON, Yoshiro Masuda, Hiromitsu Watanabe
-
Patent number: 8318699Abstract: The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-? mediated conditions.Type: GrantFiled: January 31, 2006Date of Patent: November 27, 2012Assignees: The Trustees Of The University Of Pennsylvania, Cephalon, Inc.Inventors: Mark I Greene, Ramachandran Murali, Xin Cheng, Raphael Ottenbrite, Yingxin Xiao
-
Publication number: 20120289471Abstract: The present invention is directed to novel therapeutic compounds comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. These high therapeutic index derivatives have the same utility as the drug from which they are made, and they have enhanced pharmacological and pharmaceutical properties. In fact, the novel drug derivatives of the present invention enhance at least one therapeutic quality, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.Type: ApplicationFiled: April 18, 2012Publication date: November 15, 2012Applicant: SIGNATURE R&D HOLDINGS, LLCInventor: V. Ravi Chandran
-
Publication number: 20120283325Abstract: Disclosed herein is the surprising and unexpected discovery that mannitol inhibits the growth of impurities and enhances shelf life of ezatiostat hydrochloride formulations.Type: ApplicationFiled: April 18, 2012Publication date: November 8, 2012Inventor: Robert T. Lum
-
Publication number: 20120277308Abstract: This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins. It inhibits excess adhesion and inhibits cell attachment. It modulates angiogenesis. The compounds also use as mediator of cell adhesion receptor, cell circulating, cell moving and inflammatory diseases.Type: ApplicationFiled: July 15, 2011Publication date: November 1, 2012Applicant: PACIFIC ARROW LIMITEDInventors: Pui-Kwong Chan, May Sung Mak
-
Patent number: 8299119Abstract: Compounds having useful biological activity, particularly antioxidant and anti-inflammatory activity, derived from Centipeda cunninghamii, and biologically active derivatives thereof, pharmaceutical compositions comprising these compounds, and prophylactic and therapeutic use of the compounds.Type: GrantFiled: November 29, 2006Date of Patent: October 30, 2012Assignee: Bio-Active Export Pty. Ltd.Inventors: David Leach, Lesley Stevenson, Brigitte Gabriel, Karren Beattie
-
Patent number: 8299034Abstract: Compositions and methods for maintenance of bone health or prevention, alleviation and/or treatment of bone disorders are presented. The present invention also provides the manufacture of a nutritional product, a supplement or a medicament for promoting bone growth or for the maintenance of bone health and methods regarding same. In an embodiment, the present invention provides a composition comprising an active ingredient having an effective amount of a plant or plant extract containing at least one phytochemical having the ability to induce bone morphogenic protein expression.Type: GrantFiled: February 25, 2008Date of Patent: October 30, 2012Assignee: Nestec S.A.Inventors: Elizabeth Offord Cavin, Gary Williamson, Didier Courtois, Bernard Lemaure, Andre Touche, Grace Ing Soon, Laurent Ameye
-
Publication number: 20120251632Abstract: The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible bronchospasm, severe acute bronchospasm, or acute exacerbation of asthma. The method includes administering to an individual suffering from an acute respiratory attack an effective amount of bedoradrine or a pharmaceutically acceptable salt thereof in combination with a standard of care (SOC) treatment regimen.Type: ApplicationFiled: June 15, 2012Publication date: October 4, 2012Inventors: Kazuko MATSUDA, Yuichi Iwaki, Kirk W. Johnson
-
Publication number: 20120251462Abstract: The present invention relates to rosmarinic acid for use in a method for smoker dehabituation, wherein the rosmarinic acid is preferably in the form of a dried, aqueous extract of leaves of lemon balm (Melissa officinalis). In addition, the present invention relates to foods and food supplements for use in a method for smoker dehabituation, wherein these foods and food supplements contain rosmarinic acid, in particular rosmarinic acid in the form of a dried, aqueous extract of leaves of lemon balm (Melissa officinalis).Type: ApplicationFiled: April 2, 2012Publication date: October 4, 2012Applicant: Cognis IP Management GmbHInventors: Ann-Kathrin Trierweiler, Bernhard Mueller
-
Publication number: 20120251496Abstract: Ezatiostat is useful for inhibiting multiple myeloma cell proliferation and treating multiple myeloma, alone or when added together with another anti-myeloma drug.Type: ApplicationFiled: March 20, 2012Publication date: October 4, 2012Inventor: Michael M. Wick
-
Publication number: 20120245506Abstract: The present document describes methods of use of photo activated compositions for oral disinfection and/or treatments which comprise at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmacologically acceptable carrier.Type: ApplicationFiled: July 19, 2009Publication date: September 27, 2012Inventors: Remigio Piergallini, Nikolaos Loupis
-
Patent number: 8273748Abstract: An amino alcohol derivative useful as an excellent immunosuppressive agent is provided. As a result of intensive research to create a highly safe compound which has an excellent immunosuppressive activity, it was discovered that an amino alcohol derivative represented by the general formula (1), has excellent immunosuppressive activity.Type: GrantFiled: August 7, 2007Date of Patent: September 25, 2012Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Yasushi Kohno, Kiyoshi Fujii, Tatsuhiro Saito, Kazuhiko Kuriyama, Tokutarou Yasue
-
Patent number: 8269034Abstract: Active compounds of Formula I are described: wherein: R1 and R2 are each independently C1-C4 alkyl; or R1 and R2 together form a C2-C7 alkylene chain; and Z is a non-steroidal anti-inflammatory drug (NSAID); along with pharmaceutically acceptable salts and prodrug thereof, and methods of using the same.Type: GrantFiled: July 6, 2011Date of Patent: September 18, 2012Assignee: Wake Forest University Health SciencesInventor: S. Bruce King
-
Patent number: 8268884Abstract: The present invention relates to compounds represented by formula (I), or isomers, prodrugs, pharmaceutically acceptable salts, solvates or hydrates thereof: in which each substituent of formula (I) is as defined in the specification. The present invention also relates to preparation methods of compounds represented by formula (I), a pharmaceutical composition comprising compounds represented by formula (I) and usage of compounds represented by formula (I) for treating chronic neurodegenerative diseases such as Alzheimer's disease and other diseases induced by aggregation or deposition of ?-amyloid peptide.Type: GrantFiled: February 5, 2007Date of Patent: September 18, 2012Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Guochao Liao, Junhai Xiao, Aihua Nie, Lili Wang, Wu Zhong, Zhibing Zheng
-
Patent number: 8263809Abstract: The present invention relates to an improved process for the preparation of 3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol monohydrochloride.Type: GrantFiled: July 23, 2007Date of Patent: September 11, 2012Assignee: Gruenenthal GmbHInventor: Wolfgang Hell
-
Publication number: 20120219598Abstract: The invention encompasses micelle assemblies, compositions having micelle assemblies, and methods for preparing micelle assemblies and compositions thereof. The invention also includes compounds of the formula I: A-X—Y—Z—R1 ??(I) The invention includes methods of encapsulating molecules using the compounds of the invention.Type: ApplicationFiled: February 22, 2012Publication date: August 30, 2012Inventors: Kathryn E. Uhrich, Prabhas Moghe, Sarah Sparks, Sarah Hehir, Li Gu, Nicole Iverson, Nicole Plourde
-
Publication number: 20120220596Abstract: The present invention provides cysteine and cystine prodrugs for the treatment of schizophrenia and drug addiction. The invention further encompasses pharmaceutical compositions containing prodrugs and methods of using the prodrugs and compositions for treatment of schizophrenia and drug addiction.Type: ApplicationFiled: May 7, 2012Publication date: August 30, 2012Applicants: UWM RESEARCH FOUNDATION, INC., MARQUETTE UNIVERSITYInventors: James M. Cook, David A. Baker, Wenyuan Yin, Edward Merle Johnson, II
-
Publication number: 20120208882Abstract: The invention describes novel pharmaceutically acceptable salt forms of camostat, processes for lyophilisation, taste-masked formulations, nebulised formulations and the use of each of the fore-going in the treatment of respiratory diseases, particularly cystic fibrosis and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: February 14, 2012Publication date: August 16, 2012Inventors: Henry Luke Danahay, Darren Mark LeGrand, David C. Tully, Jennifer Leslie Harris, Silvia Heuerding, Dilraj Singh, Janet Catherine Maas, Juergen Roettele, Jean-Louis Reber, Stéphanie Monnier
-
Publication number: 20120202756Abstract: The present invention relates to prodrugs of a wide variety of drugs and pharmaceutical compositions containing such prodrugs. Methods for minimizing locally mediated (from within the gut lumen) adverse gastrointestinal events associated with the underivatised drug and increasing the sustainment of plasma drug levels with the aforementioned prodrugs are also provided. Thus, the present invention relates to the use of prodrugs of a wide diversity of drugs (other than opioids) to transiently inactivate them and so reduce directly, locally mediated adverse gastrointestinal (GI) side-effects normally evident after administration of the parent compound. Additionally, such prodrugs may confer improved pharmacokinetics.Type: ApplicationFiled: October 5, 2011Publication date: August 9, 2012Inventors: Richard Franklin, Martin Quibell, Robert G. Tyson, Bernard T. Golding
-
Publication number: 20120201803Abstract: A process for forming a solid electrolytic capacitor and an electrolytic capacitor formed by the process. The process includes: providing an anode wherein the anode comprises a porous body and an anode wire extending from the porous body; applying a thin polymer layer onto the dielectric, and forming a dielectric on the porous body to form an anodized anode; applying a first slurry to the anodized anode to form a blocking layer wherein the first slurry comprises a first conducting polymer with an median particle size of at least 0.05 ?m forming a layer of crosslinker on the blocking layer; and applying a layer of a second conducting polymer on the layer of crosslinker.Type: ApplicationFiled: September 15, 2011Publication date: August 9, 2012Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventors: Shalini Sharma, James Dennen O'Neil, Reid W. von Borstel, Ramchandran Arudchandran
-
Publication number: 20120196929Abstract: The present invention relates to rosmarinic acid and to the derivatives thereof, expressed by the compounds of general formula (I), for the use thereof to prevent and/or treat disorders caused by ciguatoxin poisoning and for preparing a pharmaceutical composition for preventing and/or treating disorders caused by ciguatoxin poisoning.Type: ApplicationFiled: July 21, 2010Publication date: August 2, 2012Applicant: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENTInventors: Dominique Laurent, Serge Pauillac, Mireille Chinain, Taiana Darius, Shilpa Kumar-Roine
-
Patent number: 8227451Abstract: The present invention relates to new phenylacetic acid inhibitors of cyclooxygenase activity, pharmaceutical compositions thereof, and methods of use thereof.Type: GrantFiled: November 11, 2009Date of Patent: July 24, 2012Assignee: Auspex PharmaceuticalsInventors: Thomas G. Gant, Manouchehr M. Shahbaz
-
Publication number: 20120184616Abstract: The present invention relates to the field of therapeutic methods, compositions and uses thereof, that affect, directly or indirectly, the behavior of LRP receptors. These compositions and methods result in the treatment of inflammatory, immunological and metabolic conditions. More particularly, the methods and compositions of the invention are directed to the identification of small molecules, drugs and/or pharmacological agents that affect the Wnt pathway by affecting normal complex formation among various signaling receptors, the LRP5 and LRP6 receptor, and related ligands.Type: ApplicationFiled: August 7, 2008Publication date: July 19, 2012Inventors: Elazar Rabbani, Xiaofeng Li, Dakai Liu, Yazhou Zhang, Richard Jin, Riddhi Bhattacharyya, Wei Cheng, James J. Donegan
-
Publication number: 20120178697Abstract: The Wnt signaling pathways are involved in embryo development as well as in tumorigenesis. Dishevelled (Dvl) tranduces Wnt signals from the receptor Frizzled (Fz) to downstream components in canonical and non-canonical Wnt signaling pathways, and the Dvl PDZ domain plays an essential role in both pathways, and the Dvl PDZ domain binds directly to Fz receptors. In the present invention using NMR-assisted virtual ligand screening, several compounds were identified and were found to bind to the Dvl PDZ domain. Molecular dynamics simulation was used to analyze the binding between the PDZ domain and these compounds in detail. These compounds provide a basis for rational design of high-affinity inhibitors of the PDZ domain, which can block Wnt signaling by interrupting the Fz-Dvl interaction.Type: ApplicationFiled: April 1, 2005Publication date: July 12, 2012Inventors: Jie Zheng, Jufang Shan, Dianqing Wu
-
Patent number: 8217075Abstract: 2-amino-2-phenyl-alkanol ester derivatives of general formula (I) in which: R1 is H, straight or branched 1 to 4C alkyl, straight or branched 2 to 4C alkyl substituted by OH, alkoxy, alkylthio, acyloxy, NH2, alkylamino, dialkylamino, alkylcarbamoyloxy, alkoxycarbonylamino, ureido or alkylureido, R2 is a —CO—R radical in which R is H, alkyl, aryl, heterocyclyl, benzyl or heterocyclylmethyl, or R2 is a —CO—Y—R4 radical for which Y is —O—, —S—, —NH—, -Nalk- for which alk is straight or branched (1 to 4C) alkyl, and R4 is alkyl, aryl, aralkyl or heterocyclylalkyl, capable of being substituted by one or more halogen atoms or OH radicals, straight or branched (1 to 4C) alkyl, alkoxy, alkylthio, acylaminoalkylthio, alkoxycarbonyl or acylamino (1 to 4C) straight or branched, or oxo, or capable of being substituted by R5COO— in which R5 is alkyl optionally substituted by benzyloxycarbonylamino, acylamino or by an amino acid residue, or represents an heterocyclyl radical, or R2 is alkyl (2 to 4C) substituted by OH, alkType: GrantFiled: January 27, 2009Date of Patent: July 10, 2012Assignee: OroxcellInventors: Jean Pachot, Christophe Dini, Alexis Denis
-
Publication number: 20120165279Abstract: A pharmaceutical composition for preventing or treating hepatitis C is provided, including oleanolic acid derivatives as an active ingredient and a pharmaceutically acceptable carrier. A method for preventing or treating hepatitis C in a subject in need thereof is also provided by administering the subject the pharmaceutical composition given above.Type: ApplicationFiled: October 26, 2011Publication date: June 28, 2012Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Lain-Tze Lee, Shau-Feng Chang, Zong-Keng Kuo, Hui-Ping Tsai
-
Publication number: 20120157523Abstract: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.Type: ApplicationFiled: October 14, 2011Publication date: June 21, 2012Applicant: XenoPort, Inc.Inventors: Archana Gangakhedkar, Xuedong Dai, Noa Zerangue, Peter A. Virsik
-
Publication number: 20120149753Abstract: Disclosed herein are isolated compounds or pharmaceutically acceptable salts thereof, which exhibit immunostimulatory or anti-inflammatory effects. The compounds are isolated from the fruiting body of A. camphorata in a solid culture. Also disclosed are methods of stimulating immune responses and/or treating an inflammatory disorder with these compounds and pharmaceutical compositions including the compounds or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: February 16, 2012Publication date: June 14, 2012Applicant: Well Shine Biotechnology Development Co,, Ltd.Inventors: Yueh-Hsiung Kuo, Bi-Fong Lin
-
Patent number: 8193242Abstract: (2R)-2-Phenylcarbonyloxypropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and crystalline form thereof, methods of making the same, pharmaceutical compositions thereof, and methods of using the same to treat diseases or disorders such as Parkinson's disease are provided.Type: GrantFiled: January 20, 2011Date of Patent: June 5, 2012Assignee: XenoPort, Inc.Inventors: Jia-Ning Xiang, Xuedong Dai, Cindy X. Zhou, Jianhua Li, Mark Q. Nguyen
-
Publication number: 20120135094Abstract: The present invention relates to bioactivity-guided isolation and identification of bioactive compounds from oregano and mint plants, in particular, rosmarinic acid, oleanolic acid and ursolic acid, and use of these compounds or combinations thereof as anti-inflammatory agents for the treatment of conditions related to pain and inflammation and/or as ingredients of dietary supplements. The invention also relates to optimization of the methods for qualitative and quantitative analysis of the bioactive compounds in oregano and mint plants. In particular, this invention introduces an LC/MS (SIM mode) method to achieve co-quantitation of the three organic acids using a unique tandem column system. In addition, the invention also relates to the methods for recovering various water-soluble polyphenols and triterpenes from aromatic plants.Type: ApplicationFiled: May 14, 2010Publication date: May 31, 2012Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: James E. Simon, Diandian Shen, Hector Rodolfo Juliani, Qingli Wu
-
Publication number: 20120129931Abstract: This invention relates to caffeic acid derivatives and improving viability of neuronal cells by contacting neuronal cells by caffeic acid derivatives as shown in the specification.Type: ApplicationFiled: November 15, 2011Publication date: May 24, 2012Applicant: ChemiGenInventors: Junyi Liu, Yangsheng Du
-
Publication number: 20120122977Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, X, X1, s and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.Type: ApplicationFiled: November 11, 2011Publication date: May 17, 2012Applicant: NOVARTIS AGInventors: Gary Mark COPPOLA, Rajeshri Ganesh KARKI, Toshio KAWANAMI
-
Publication number: 20120122844Abstract: The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.Type: ApplicationFiled: November 11, 2011Publication date: May 17, 2012Applicant: NOVARTIS AGInventor: Shi Yin FOO
-
Publication number: 20120115947Abstract: Acne lesions, whether of inflammatory and/or non-inflammatory type, are simultaneously or sequentially treated and their number reduced, via daily topical regimen, with the combination or association of adapalene or pharmaceutically acceptable salt thereof and benzoyl peroxide (BPO).Type: ApplicationFiled: January 17, 2012Publication date: May 10, 2012Applicant: Galderma Research & DevelopmentInventors: Marie-Line Abou Chacra Vernet, Denis Gross, Christian Loesche, Michel Poncet
-
Publication number: 20120100122Abstract: A pharmaceutical composition containing a mitochondrial electron transport chain enhancer (or an antioxidant) and a compound of formula (I) shown in the specification. This pharmaceutical composition can be used to treat neurodegenerative disorders.Type: ApplicationFiled: October 18, 2011Publication date: April 26, 2012Applicant: ChemiGenInventor: Yansheng Du
-
Publication number: 20120095051Abstract: This invention provides a compound having the structure wherein ?, ?, X, Y, and R1-R11 are defined herein. This invention also provides a pharmaceutical composition comprising the above compounds, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (MMP), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting NF?-B activation in a population of cells.Type: ApplicationFiled: May 14, 2010Publication date: April 19, 2012Inventors: Francis Johnson, Lorne Golub
-
Patent number: 8148420Abstract: Methods of stimulating immune response or treating an inflammatory disorder with one of a number of the compounds disclosed herein or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 30, 2010Date of Patent: April 3, 2012Assignee: Well Shine Biotechnology Development Co., Ltd.Inventors: Yueh-Hsiung Kuo, Bi-Fong Lin
-
Publication number: 20120071550Abstract: The present invention provides a therapeutic composition comprising one or more polyphenols and one or more carotenoids selected from the group consisting of lutein, lycopene and beta-carotene. The invention also provides methods for inhibiting or reducing the production of superoxide ions, NO, TNF-alpha and/or PGE2 in a mammalian subject comprising administering to said subject the aforementioned therapeutic composition.Type: ApplicationFiled: July 18, 2011Publication date: March 22, 2012Applicant: LYCORED LTD.Inventors: Morris Zelkha, Rachel Levy, Esther Paran, Yoav Sharoni, Joseph Levy
-
Patent number: 8138376Abstract: The present invention relates to an improved process for the preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine which is an intermediate for the preparation of the analgesic tapentadol.Type: GrantFiled: July 23, 2007Date of Patent: March 20, 2012Assignee: Janssen Pharmaceutica, NVInventors: Walter Ferdinand Maria Filliers, Rudy Laurent Maria Broeckx